NCT02845843View on ClinicalTrials.gov

MERS-CoV Infection tReated With A Combination of Lopinavir /Ritonavir and Interferon Beta-1b

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

May 31, 2020

Study Completion Date

May 31, 2020

Conditions
Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
Interventions
DRUG

Combination of Lopinavir /Ritonavir and Interferon beta-1b

Lopinavir /Ritonavir 400mg +100 mg / ml twice daily for 14 days and Interferon beta-1b 0.25 mg subcutaneous every alternate day for 14 days

DRUG

Placebo

Same characteristics as Lopinavir /Ritonavir and Interferon beta-1b to maintain blinding

Trial Locations (2)

11426

Intensive Care Unit, King Abdulaziz Medical City, National Guard Health Affairs, Riyadh

22490

King Abdullah International Medical Research Center, Riyadh

All Listed Sponsors
lead

King Abdullah International Medical Research Center

OTHER

NCT02845843 - MERS-CoV Infection tReated With A Combination of Lopinavir /Ritonavir and Interferon Beta-1b | Biotech Hunter | Biotech Hunter